Precision medicine in laryngeal cancer: protocol of the laryngeal cancer cohort (LARCH).
adult radiotherapy
epidemiology
head & neck imaging
head & neck surgery
head & neck tumours
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
13 01 2023
13 01 2023
Historique:
entrez:
13
1
2023
pubmed:
14
1
2023
medline:
18
1
2023
Statut:
epublish
Résumé
Laryngeal cancer disproportionately affects socioeconomically disadvantaged patients. Treatment can render a patient nil by mouth or in need of a permanent tracheostomy. In the past 30 years, survival has remained at best static and at worst it has declined. Currently, there is no method of prognosticating how a patient will respond to treatment.The LARyngeal Cancer coHort (LARCH) aims to establish how survival and quality-of-life outcomes compare between surgery and (chemo)radiotherapy in early and advanced laryngeal cancer and how the presenting features of laryngeal cancer influence oncological, functional and quality-of-life outcome. This study is the first enhanced laryngeal cancer disease cohort. In the initial phase, we aim to deliver a prospective cohort study of 150 patients in 8 centres over a 3-year period.Patient, tumour, quality-of-life and laryngeal functional data will be collected from patients with squamous cell carcinoma of the larynx at baseline, 6, 12 and 24 months. Multiple logistic regression analyses will be used to quantify locoregional control and identify factors associated with control overall and by treatment modality and identify factors associated with quality of life overall and by treatment modality. Most interventions take place as part of routine care, with LARCH providing a mechanism for recording this data centrally. When successfully recruiting in the North of England, we plan to roll out LARCH nationwide; in the future, LARCH can be used as a trial platform in the disease. The results will be submitted for publication in high-impact international peer-reviewed journals and presented to scientific meetings. Access to the anonymised LARCH dataset by other researchers will be publicised and promoted. ISRCTN27819867.
Identifiants
pubmed: 36639211
pii: bmjopen-2022-067561
doi: 10.1136/bmjopen-2022-067561
pmc: PMC9843189
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e067561Subventions
Organisme : Medical Research Council
ID : MR/V037528/1
Pays : United Kingdom
Informations de copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Br J Radiol. 2021 Dec;94(1128):20210499
pubmed: 34586899
Br J Cancer. 2008 Sep 23;99 Suppl 1:S35-7
pubmed: 18813254
Front Oncol. 2019 Aug 29;9:827
pubmed: 31555588
J Clin Oncol. 2006 Feb 1;24(4):593-8
pubmed: 16380415
Br J Cancer. 2004 Oct 18;91(8):1477-81
pubmed: 15467772
N Engl J Med. 2003 Nov 27;349(22):2091-8
pubmed: 14645636
N Engl J Med. 1991 Jun 13;324(24):1685-90
pubmed: 2034244
Laryngoscope. 2006 Sep;116(9 Pt 2 Suppl 111):1-13
pubmed: 16946667
Eur Arch Otorhinolaryngol. 2013 Aug;270(8):2333-7
pubmed: 23334205
Head Neck. 2019 Jun;41(6):1908-1917
pubmed: 30620423
Appl Health Econ Health Policy. 2015 Aug;13(4):359-67
pubmed: 25691128